High-grade glioma prognosis [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== High-grade glioma prognosis ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1PGhx32McSRGSlPQVYT0c5a1O3clXFqRiXB0XdA4jXMRWpEYYl/?limit=15&utm_campaign=pubmed-2&fc=20241129051941}}
----

----


5-year survival rates of 30.9% for [[WHO grade III]] glioma and 6.6% for [[WHO grade IV]] glioma.
----

see [[Glioblastoma prognosis]].
----
[[Anaplastic astrocytoma outcome]]
----
In pretreated [[high-grade glioma]]s, right hemisphere lesions are associated with reduced [[HRQoL]] scores in most functional domains except communication ability, compared to tumors of the left hemisphere. These relationships are mainly observed for [[T2]]/[[FLAIR]] lesions involving structural and functional networks in the right hemisphere. The data suggest that sparing the right hemisphere from treatment-related tissue damage may improve HRQoL in glioma patients
((Heinzel A, Mottaghy FM, Filss C, Stoffels G, Lohmann P, Friedrich M, Shah NJ, Caspers S, Lucas CW, Ruge MI, Galldiks N, Fink GR, Langen KJ, Kocher M. The impact of brain lesions on health-related quality of life in patients with WHO CNS grade 3 or 4 glioma: a lesion-function and resting-state fMRI analysis. J Neurooncol. 2023 Feb 7. doi: 10.1007/s11060-023-04254-1. Epub ahead of print. PMID: 36750534.))
----
Diagnosis and treatment of [[high-grade glioma ]] with [[leptomeningeal disease]] are challenging. Aggressive control of [[ICP]] followed by early initiation of standard concurrent [[chemoradiotherapy]] (CCRT) seems to help improve symptoms. However, despite aggressive treatment, the [[prognosis]] is poor. A [[multicenter]] [[trial]] and research may be necessary to create a standardized [[protocol]] for this disease
((Kwon JE, Hwang K, Go KO, Wee CW, Kim IA, Kim YJ, Choe G, Choi BS, Han JH, Kim CY. Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study. Brain Tumor Res Treat. 2020 Oct;8(2):77-82. doi: 10.14791/btrt.2020.8.e18. PMID: 33118340.)).